A genetic risk score is associated with statin-induced low-density lipoprotein cholesterol lowering by Leusink, Maarten et al.
                          Leusink, M., Maitland-Van Der Zee, A. H., Ding, B., Drenos, F., Van Iperen,
E. P. A., Warren, H. R., ... Onland-Moret, N. C. (2016). A genetic risk score
is associated with statin-induced low-density lipoprotein cholesterol
lowering. Pharmacogenomics, 17(6), 583-591. DOI: 10.2217/pgs.16.8
Peer reviewed version
Link to published version (if available):
10.2217/pgs.16.8
Link to publication record in Explore Bristol Research
PDF-document
This is the author accepted manuscript (AAM). The final published version (version of record) is available online
via Future at http://www.futuremedicine.com/doi/10.2217/pgs.16.8. Please refer to any applicable terms of use of
the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms.html
A genetic risk score is associated with statin-induced 
LDL-cholesterol lowering  
Short title: Genetic risk score for LDL-cholesterol lowering 
Maarten Leusink, PhD 1,2, AnkeH. Maitland-van der Zee, PharmD, PhD 1, Bo Ding, PhD 3, Fotios Drenos, 
PhD 4,5, Erik P.A van Iperen, MSc 6,7, Helen R. Warren, PhD 8,9, Mark J. Caulfield, MD 8,9, L. Adrienne 
Cupples, PhD 10,11, Mary Cushman, MSc, MD 12, Aroon D. Hingorani, PhD 13, Ron C Hoogeveen, PhD 14, G. 
Kees Hovingh, PhD 15, Meena Kumari, PhD 13, Leslie A Lange, PhD 16, Patricia B. Munroe, PhD 8,9, Fredrik 
Nyberg, MPH, MD, PhD 3,17, Pamela J Schreiner, PhD 18, Suthesh Sivapalaratnam, PhD 15, Paul I.W. de 
Bakker, PhD 2,21, Anthonius de Boer, MD, PhD 1, Brendan J. Keating, DPhil 22,23, Folkert W. Asselbergs, 
MD, PhD 6,19,20, N. Charlotte Onland-Moret, PhD 2  
 
1 Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of 
Science, Utrecht University, Utrecht, the Netherlands 2 Julius Center for Health Sciences and Primary Care, University Medical 
Center Utrecht, Utrecht, The Netherlands 3 Observational Research Center, Payer & Real World Evidence, Global Medicines 
Development, AstraZeneca R&D, Mölndal, Sweden 4 Centre for Cardiovascular Genetics, Institute of Cardiovascular Science, 
University College London, London, UK 5 MRC Integrative Epidemiology Unit, University of Bristol, Bristol,UK 6 Durrer Center for 
Cardiogenetic Research, ICIN-Netherlands Heart Institute, Utrecht, The Netherlands 7 Department of Clinical epidemiology, 
Biostatistics and Bioinformatics, Academic Medical Center Amsterdam, Amsterdam, The Netherlands 8 Clinical Pharmacology, 
William Harvey Research Institute, Barts and The London, Queen Mary University of London, London, UK 9 NIHR Barts 
Cardiovascular Biomedical Research Unit, Queen Mary University of London, London, UK 10 Boston University, Boston, MA, USA 
11 The National Heart, Lung, and Blood Institute Framingham Heart Study, Framingham, MA, USA 12 Departments of Medicine 
and Pathology, University of Vermont, Burlington, VT, USA 13 Department of Epidemiology & Public Health, UCL Institute of 
Epidemiology & Health Care, University College London, London, UK 14 Baylor College of Medicine, Department of Medicine, 
Division of Atherosclerosis & Vascular Medicine, Houston, TX, USA 15 Department of Vascular Medicine, Academic Medical 
Center Amsterdam, Amsterdam, the Netherlands 16 Department of Genetics, University of North Carolina School of Medicine at 
Chapel Hill, Chapel Hill, NC, USA 17 Occupational and environmental medicine, Department of Public Health and Community 
Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden 18 School of Public 
Health, University of Minnesota, Minneapolis, MN, USA 19 Department of Cardiology, Division Heart and Lungs, University 
Medical Center Utrecht, Utrecht, The Netherlands 20 Institute of Cardiovascular Science, Faculty of Population Health Sciences, 
University College London, London, United Kingdom 21 Department of Medical Genetics, University Medical Center Utrecht, 
Utrecht, The Netherlands 22 The Center for Applied Genomics, Abramson Research Center, The Children's Hospital of 
Philadelphia, Philadelphia, PA, USA 23 Division of Transplantation, Department of Surgery, Hospital of the University of 
Pennsylvania, Philadelphia, PA, USA  
Correspondence: 
N. Charlotte Onland-Moret 
Visiting address: Universiteitsweg 100, 3584 CG, Utrecht, The Netherlands 
Mail address: PO Box 85500, 3508 GA Utrecht, The Netherlands 
Tel: +31(0)88 75 593 67 
Mail: N.C.Onland@umcutrecht.nl 
 
Number of words: 2419. References: 28. Figures: 1. Tables: 3 
Keywords 
statin therapy, pharmacogenetics cholesterol, risk score 
Page 2 of 19 
 
Abstract 
Aims 
To find new genetic loci associated with statin response, and to investigate the association of a genetic 
risk score (GRS) with this outcome. 
Patients & Methods 
In a discovery meta-analysis (five studies, 1,991 individuals), we investigated the effects of 
approximately 50,000 SNPs on statin response, following up associations with p < 1e-4 (three 
independent studies, 5,314 individuals). We further assessed the effect of a GRS based on SNPs in 
ABCG2, LPA, and APOE.  
Results 
No new SNPs were found associated with statin response. The GRS was associated with reduced statin 
response: 0.0394 mmol/L per allele (95%CI 0.0171;0.0617, p=5.37e-4). 
Conclusions  
The GRS was associated with statin response, but the small effect size (~2% of the average LDLc 
reduction) limits applicability.  
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Introduction 
The primary goal of statin therapy is to reduce plasma low-density lipoprotein cholesterol (LDLc) levels, 
thereby lowering the risk of cardiovascular events. Statin treatment has proven effective in reducing risk 
for major coronary events and all-cause mortality (average risk reductions of 27% and 15%, respectively) 
[1,2]. However, the response to statin therapy shows a degree of interindividual variability influenced by 
genetic variation and environmental factors [3,4].  
A better understanding of the biological pathways and determinants involved in this variation in statin 
response could lead to improved treatment. Genome-wide association studies (GWAS) have identified 
many (95+) loci associated with plasma lipid and lipoprotein traits, including several not previously 
known to be related to lipoprotein metabolism [5]. In contrast, studies searching for single nucleotide 
polymorphisms (SNPs) related to statin response have yielded a relatively low number of robust results. 
Evidence from several studies shows that the ε4 allele of APOE is associated with decreased LDLc 
lowering by statin therapy [3,6–9]. Additionally, SNPs at ABCG2 and LPA were associated with LDLc 
response at the level of genome-wide significance [8,9]. These GWAS have generally been performed in 
data from randomized controlled trials (RCTs), and it is not certain if these results also apply to statin 
users in the general population. In addition, other approaches than hypothesis-free GWAS genotyping 
across the genome may be a useful complement to uncover further associated genetic variants. 
Using a gene-centric approach, we therefore aimed to identify additional genetic associations underlying 
interindividual variation in statin response. To this end, we performed a meta-analysis of five studies 
comprising 2,159 individuals of European ancestry by using the candidate-gene ITMAT-Broad-CARe (IBC) 
array, also known as the CardioChip or the Human CVD BeadArray [10]. This array aims to capture 
genetic diversity related to cardiovascular, inflammatory, and metabolic phenotypes in greater depth 
than classic hypothesis-free GWAS using approximately 50,000 SNPs selected across  ~2,000 candidate 
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loci. Compared to normal GWAS arrays, the equal or greater marker density might permit a better 
identification of multiple functional polymorphisms, or their proxies, at each locus. 
Compared with single SNPs, genetic risk scores consisting of multiple SNPs previously identified by 
GWAS increase statistical power to find associations, and summarize the total genetic effect; therefore 
these risk scores might be of more clinical value than single SNPs. However, as the single SNPs robustly 
associated with statin response were found in GWA studies with RCT participants, the value of a genetic 
risk score in the general population is at present unclear. We therefore investigated whether a genetic 
risk score is associated with statin response in the lowering of LDLc response in observational studies as 
well as in RCTs. 
Methods 
Study selection 
In our focus on a gene-centric discovery approach, we selected studies that used the 50k Cardiochip 
array [10] for genotyping, having more than one measurement of LDLc, information on statin use, and 
participants of European ancestry. We included five studies, the Atherosclerosis Risk in Communities 
(ARIC) study, the Framingham Heart Study (FHS), the Multi-Ethnic Study of Atherosclerosis (MESA), 
Whitehall II (WHII), and AMC-PAS (Academic Medical Centre Amsterdam Premature Atherosclerosis 
Study). All these studies were observational. Replication of the results was sought in other studies, 
detailed below. The baseline measurement was defined in these studies as the last measurement of 
LDLc before reporting use of statins. The baseline value is therefore not necessarily measured on the 
same visit for all participants. The on-statin measurement was defined as the first measurement of LDLc 
after the first report of statin use. We then calculated LDLc change (delta LDLc) by subtracting the 
baseline value from the on-statin value. Details of the set-up and analysis for each study can be found in 
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the Supplementary Material. Informed consent for DNA analysis was received from each respective local 
institutional and/or national ethical review board. 
Genotyping and Quality Control 
Genotyping was performed using the gene-centric IBC array [10]. Several studies have been published 
using this array and have confirmed previously established associations and identified new associations 
of SNPs with several phenotypes and disease outcomes, including blood pressure [11], coronary artery 
disease [12,13], plasma lipids [14], and type 2 diabetes (T2D) [15]. Array data were clustered into 
genotypes with Illumina BeadStudio software. Quality-control filters were applied within each cohort at 
the sample and SNP levels and are described in the Supplementary Methods. SNPs with a call rate below 
95% or Hardy-Weinberg p-value < 1e-6 were excluded from analysis. Only SNPs with a minor allele 
frequency > 1% were included in this analysis. 
Association analysis 
We used linear regression to test the association of a SNP with LDLc change. Association testing was 
performed using an additive genetic model, adjusting for age, sex, baseline LDLc, and other relevant 
study covariates (see Supplementary Material). Samples were excluded based on ancestry outliers by 
PCA, removals of duplicates and first and second degree relatives. Each study was further adjusted for 
population stratification using the principal component approach in EIGENSTRAT [16]. Adjustment for 
baseline LDLc was necessary because many of the SNPs previously associated with statin response are 
also associated with cholesterol levels before treatment with statins. Meta-analysis was performed with 
METAL [17], using the inverse variance method and a fixed-effects model and I² as a measure of 
between-study heterogeneity [18]. To maintain the conventional 5% false-positive rate, the appropriate 
multiple-testing-corrected threshold for statistical significance was set at p < 2.4e-6, taking into account 
the ~20,500 independent tests generated for individuals of European descent [19]. We selected all SNPs 
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reaching p < 1e-4 for subsequent replication. Power calculations for the chip-wide association analysis 
were done using QUANTO [20], assuming a mean LDLc-reduction of 1.3 mmol/L with a SD of 0.6, and a 
minor allele frequency of 20%. 
Replication 
Independent replication was attempted for associations with p < 1e-4. Look-ups were performed in 
three additional studies, the UK and Irish subjects from the observational and the randomized arm of 
the Anglo Scandinavian Cardiac Outcomes Trial (ASCOT-UK RCT and ASCOT-UK OBS) and the RCT 
JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating 
Rosuvastatin), with data from a total of 5,314 individuals in the three studies. Details of characteristics 
and methodological details for cohorts can be found in the Supplementary Material. The association of 
the genetic risk score was also investigated in these replication studies.  
Risk score composition 
We calculated a genetic risk score (genetic risk score) on the basis of previous findings related to statin 
response, selecting risk alleles achieving genome-wide significance (p < 5e-8) in GWAS of LDLc change, 
replicated in at least one other study. In total, we selected 3 SNPs reported by Chasman et al [9], 
independently found by Deshmukh et al. [8] and Tomlinson et al. [21]. These SNPs were rs2231142 (a 
proxy SNP with r2 = 0.92 for rs2199936 in ABCG2), rs10455872 in LPA, and rs2075650 (a proxy SNP with 
r2 = 0.95 for rs71352238 in APOE). For all three loci, the lead SNP or a good proxy SNP (r2 > 0.8) was 
available. One of the studies, AMC-PAS, was not included in this analysis due to the unavailability of one 
of the SNPs in the risk score. 
The approach used to calculate the genetic risk score was a simple count of the alleles decreasing statin 
response, i.e. lowering the efficacy and bringing the response closer to zero. The simple count approach, 
rather than weighted scores, was chosen as SNP effects found in GWAS were similar.  
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Association of the risk score with delta LDLc was investigated using linear regression, using the risk score 
as a continuous variable. Models were adjusted for age, sex, baseline LDLc, and relevant study 
covariates (e.g. correction for population stratification with principal components) as specified in the 
Supplementary Material.  
Study-specific estimates of the risk score effect (beta) were subsequently combined using random 
effects meta-analysis with the inverse variance weighting method, using R [22] version 3.0.2 and the 
‘meta’ package [23] 3.5-0.  A p-value < 0.05 was considered to constitute a statistically significant effect. 
We used I² to quantify between-study heterogeneity [18]. 
Results 
Characteristics of studies 
For the discovery data set, we included five studies with a total of 1,991 participants (Table 1). This gave 
us 80% statistical power to detect effects of 0.125 mmol/L per allele, which is close to the effect sizes 
found by other studies [9]. LDLc levels were consistently lower on statin use compared with before 
statin use, with an average reduction of 1.18 mmol/L. In the replication phase, a total of 5,314 
participants in three studies were included with an average LDLc reduction of 1.25 mmol/L. For the risk 
score analysis, one study was excluded due to unavailable SNPs, and the total sample size was 7,121. 
Association analysis 
A total of 37,465 SNPs in five cohort studies were tested in the association analysis. No SNPs reached 
the significance threshold of p < 2.4e-6 (Figure S1: QQ-plot, Figure S2: Manhattan plot). One SNP 
reached p < 1e-4 (Table 2), rs17171676 on chromosome 7, and was taken to the replication phase. This 
SNP was not statistically significantly associated in this replication phase (replication p > 0.05), nor in a 
joint analysis of the discovery and replication phase (Table 2). 
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Association of genetic risk score 
The distribution of the risk score (Table 3) shows that only 4% of the individuals of European ancestry 
have 4 or more risk alleles, with the majority (more than 95%) having 1-3 alleles. Although statins show 
a consistent average reduction in LDLc, a higher genetic risk score is associated with a smaller change in 
LDLc due to statin treatment. The risk score decreased the effect of statins on delta LDLc by 0.0394 
mmol/L per allele (95%CI 0.0171; 0.0617), with a p-value of 5.37e-4 (Figure 1). Heterogeneity was low in 
this analysis (I2 = 18%). When adjustment for baseline LDLc was not included, the effect size was similar, 
0.0354 mmol/L per allele but with a larger 95% confidence interval (0.0054; 0.0654), which is still 
statistically significant (p = 0. 00206). The effect size was larger in the observational studies (β = 0.0509 
mmol/L per allele, 95%CI: 0.0172; 0.0847, p = 0.0031) than in the RCTs (β = 0.0391 mmol/L per allele, 
95%CI: -0.0097; 0.0880, p = 0.117). 
Discussion 
Using data from six population-based cohort studies and two RCTs, with a total of 7,305 participants, we 
investigated the effect of common genetic variation on the LDLc response to statins using a 
cardiovascular gene-centric SNP array. The LDLc lowering effect of statins we found in the whole 
population, -1.30 mmol/L, is in the range of the values reported in a large meta-analyses of clinical trials 
(from -1.08 to -1.8 mmol/L)[1,24].  
No new loci were found to be associated to LDLc response to statins. Although one locus reached a p-
value of p < 1e-4, it could be replicated. These results are consistent with a genetic model involving 
multiple genes, each with modest effects, on LDLc change. The observation that GWAS have revealed 
robust associations with statin-induced response suggests that there are genuine genetic factors but 
that much larger samples will be needed to find them with unequivocal evidence.  
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We also investigated the association of a genetic risk score, consisting of SNPs previously associated 
with statin response at the genome-wide level, with statin-induced LDLc lowering. The direction of 
effect of the risk score agreed with what was previously found. However, the effect was small, 0.0313 
mmol/L per extra allele, which is about 2% of the total lowering of LDLc we found in the studies included 
in our analysis. Furthermore, more than 95% of individuals with European ancestry only have 1-3 risk 
alleles, resulting in a maximum of 0.09 mmol/L difference in statin response. The small effect of the risk 
score, the modest effective range of a risk score based on 3 SNPs, and the fact that LDLc was 
substantially reduced in most participants starting statin therapy, suggest that the possible role of 
genetics in the prediction of statin efficacy is small. The same conclusion was also reached by 
investigators studying the effects of single SNPs [8,9,25]. This study adds to the existing knowledge that 
taking the genetic background of a patient into account when prescribing statins, based on the known 
SNPs that affect statin-efficacy, does not seem justified. Although larger sample sizes in future studies 
may well result in the identification of additional loci that influence LDLc response, it seems unlikely that 
a revised genetic risk score would explain a sufficiently large fraction of the observed interindividual 
variation in LDLc response for it to be clinically useful. These limitations notwithstanding, genetic 
research into adverse events such as myopathy [26] and rhabdomyolysis might be used to predict and 
prevent these side effects, as has been done for other drugs and side effects, as effect sizes for adverse 
drug reactions may be much larger [27,28]. 
It is important to distinguish between direct genetic effects on (baseline) LDLc and genetic effects on 
statin-induced LDLc reduction.  These can be difficult to separate when there are also associations with 
baseline LDLc, as is the case for the SNPs used in the risk score [5,9].  Adjusting for baseline LDLc values 
slightly increased the effect of the risk score, and narrowed the 95% CI. This indicates that associations 
with LDLc change can be obscured by effects of SNPs on baseline LDLc, and underscores the importance 
of this adjustment. 
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A strong point of this study is that it includes evidence from both observational cohort studies and 
clinical trials, demonstrating that the genetic risk score has a similar effect in both types of studies. A 
limitation of this study, however, is that we were not able to investigate the genetic effects for the 
different types of statins separately. This is partly a result of lack of data: the studies in the discovery 
phase have incomplete dosing and statin type data or complete absence of it. This is different from the 
data of clinical trials ASCOT and JUPITER (10 mg/d atorvastatin and 20mg/d rosuvastatin, respectively). 
However, when we would restrict our analyses to those subjects with information on dose and type of 
statin, the power reduction due to a lower participant count would negatively impact the possible 
identification of SNPs affecting statin effectiveness. Further, the study is small compared to meta-
analyses of main SNP effects, which now typically include more than 100,000 participants [5]. This is a 
result of the fact that only a subset of the participants in observational studies (and also of placebo-
controlled statin trials) is prescribed statin medication. Additionally, several population-based studies 
only have cholesterol measures at only one time point, excluding the possibility of investigating 
longitudinal changes in LDLc, while other studies do not have (reliable) information on drug use. For 
pharmacogenetic research, which is hampered by relatively small sample sizes [29], it would be valuable 
if drug use data and longitudinal follow-up data were routinely collected in large samples. 
In summary, we investigated whether new individual SNPs associated with statin-induced change in 
LDLc levels could be identified from a gene-centric discovery approach; we further investigated whether 
a genetic risk score, composed of SNPs previously associated with statin response, was associated with 
statin-induced change in LDLc levels. We did not find new SNPs associated with the magnitude of statin-
induced LDLc reduction, but we found that there is a small but statistically significant association of the 
risk score with statin-induced LDLc reduction. However, use of statins lowers LDLc substantially 
regardless of genotype, and each additional allele in the genetic risk score decreases the total LDLc 
change only by 2%. Therefore, genotype-based clinical decision making for statin therapy is unlikely to 
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improve efficacy, and at this moment there is no role for genetic testing in clinical practice to guide 
statin treatment. 
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Future perspective 
To date, several polymorphisms have been found to affect response to statin therapy based on the 
achieved lowering of LDL cholesterol (LDLc). A further increase of the number of loci associated with 
LDLc response can probably be achieved with larger studies using GWAS methodology, although large 
numbers of statin users are required to effectively perform these. Because of the small effect sizes 
identified, there does not seem to be a genetically identifiable subgroup in which statins do not lower 
LDLc.  The utility of genetic research into statin response might lie more in a better understanding of 
pharmacokinetics and pharmacodynamics, and ultimately the development of new drugs, than in direct 
clinical application (e.g. choosing a drug type or dose). Alternatively, research into the (prediction of) 
adverse drug reactions side effects of statin therapy might have a faster impact on clinical decisions. 
Summary points 
Background  
 The response to statin therapy shows a degree of interindividual variability influenced by genetic variation 
and environmental factors.  
 Several studies have found genetic variants that have an effect on the statin-induced LDLc lowering.  
Patients & methods  
 We investigated the association of statin response on a cardiovascular gene-centric SNP array in a 
discovery data set consisting of five studies and 1,991 individuals, aiming to find novel associations with 
this outcome.  
 We further assessed the effect of a composite genetic risk score on statin response, based on previously 
associated SNPs in ABCG2, LPA, and APOE. 
Results: main findings 
 A genetic risk score was significantly associated with LDLc-response to statins. We found no novel SNPs to 
be significantly associated with LDLc-response to statins  
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 The small effect size of this association suggests that the applicability of this score in predicting statin 
response in clinical practice will be limited. 
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Figure legends 
Figure 1 Forest plot for the association between the genetic risk score and LDLc reduction. Analyses 
were adjusted for baseline LDLc values. 
